ABUS Arbutus Biopharma Corp

Price (delayed)

$2.83

Market cap

$474.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$458.96M

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple ...

Highlights
The debt has declined by 18% year-on-year and by 7% since the previous quarter
The company's EPS rose by 4.2% YoY
ABUS's quick ratio is up by 23% YoY but it is down by 3.3% QoQ
Arbutus Biopharma's revenue has decreased by 38% YoY and by 5% QoQ
Arbutus Biopharma's gross profit has decreased by 38% YoY and by 5% QoQ

Key stats

What are the main financial stats of ABUS
Market
Shares outstanding
167.7M
Market cap
$474.58M
Enterprise value
$458.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.97
Price to sales (P/S)
21.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.64
Earnings
Revenue
$22.24M
EBIT
-$74.75M
EBITDA
-$73.39M
Free cash flow
-$86.78M
Per share
EPS
-$0.46
Free cash flow per share
-$0.52
Book value per share
$0.71
Revenue per share
$0.13
TBVPS
$0.95
Balance sheet
Total assets
$158.64M
Total liabilities
$39.3M
Debt
$1.91M
Equity
$119.34M
Working capital
$119.28M
Liquidity
Debt to equity
0.02
Current ratio
6.34
Quick ratio
6.11
Net debt/EBITDA
0.21
Margins
EBITDA margin
-330%
Gross margin
100%
Net margin
-339.3%
Operating margin
-352.8%
Efficiency
Return on assets
-41.8%
Return on equity
-56.4%
Return on invested capital
-58.7%
Return on capital employed
-54.8%
Return on sales
-336.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-1.74%
1 week
-2.75%
1 month
11.42%
1 year
1.8%
YTD
13.2%
QTD
13.2%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$22.24M
Gross profit
$22.24M
Operating income
-$78.47M
Net income
-$75.47M
Gross margin
100%
Net margin
-339.3%
ABUS's operating margin has dropped by 102% year-on-year and by 11% since the previous quarter
The net margin has dropped by 77% year-on-year and by 9% since the previous quarter
Arbutus Biopharma's revenue has decreased by 38% YoY and by 5% QoQ
Arbutus Biopharma's gross profit has decreased by 38% YoY and by 5% QoQ

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
3.97
P/S
21.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.64
The company's EPS rose by 4.2% YoY
ABUS's price to book (P/B) is 76% higher than its 5-year quarterly average of 2.3 and 39% higher than its last 4 quarters average of 2.9
Arbutus Biopharma's equity has decreased by 18% YoY and by 11% QoQ
The price to sales (P/S) is 57% higher than the last 4 quarters average of 13.8 but 11% lower than the 5-year quarterly average of 24.4
Arbutus Biopharma's revenue has decreased by 38% YoY and by 5% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 94% YoY and by 10% QoQ
Arbutus Biopharma's return on assets has decreased by 29% YoY and by 10% QoQ
The ROE is down by 29% year-on-year and by 8% since the previous quarter
The ROIC has declined by 20% year-on-year and by 11% since the previous quarter

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
ABUS's total liabilities is down by 33% year-on-year and by 7% since the previous quarter
The company's current ratio rose by 24% YoY but it fell by 2% QoQ
The debt is 98% smaller than the equity
The debt has declined by 18% year-on-year and by 7% since the previous quarter
Arbutus Biopharma's equity has decreased by 18% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.